pharmaceutical pills will be premium-priced, while OTC supplements range from $10 to $90 per month AmazonGrandviewresearch
Some patients may prefer alternative formats, but efficacy and safety data are limited
Rezaie P, Bitarafan V, Horowitz M, Feinle-Bisset C
In the United States, about 1 in 700 babies are born with cleft lips and/or palates
Top-line trial details - ~1,700 adults with type 2 diabetes - Head-to-head vs oral semaglutide 7 mg and 14 mg - Doses tested: orforglipron 12 mg and 36 mg Primary endpoint: A1C reduction - Orforglipron 36 mg: 2.2% A1C - Oral semaglutide 14 mg: 1.4% A1C Weight loss - Orforglipron 36 mg: 19.7 lbs (9.2%) - Oral semaglutide 14 mg: 11.0 lbs (5.3%) - Roughly 7.3% greater relative weight loss Importantly, orforglipron did have HIGHER Adverse Events like nausea, diarrhea, vomiting, dyspepsia, decreased appetite, leading to more people dropping off Discontinuation due to AEs: - Orforglipron 36 mg: 9.7% - Oral semaglutide 14 mg: 4.9% Orforglipron Beats Semaglutide in Head-to-Head Trial for Diabetes, Weight Loss Eli Lilly just posted head-to-head data showing its oral GLP-1, orforglipron, beat oral semaglutide across blood sugar and weight loss in a 52-week Phase 3 trial
